drug_type
RELEVANT_DRUG
intervention_type
Biological (mRNA vaccine)
drug_description
Lipid nanoparticle–encapsulated mRNA therapeutic vaccine encoding HPV16/18 antigens, administered intramuscularly (25/75/150 µg; three doses every 2 weeks). It promotes dendritic-cell antigen presentation (MHC I/II) and robust CD8+ and CD4+ T-cell responses to clear HPV-infected dysplastic cervical epithelial cells and drive lesion regression.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Papillomavirus Vaccines
drug_category
mRNA VACCINE
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
Lipid nanoparticle–encapsulated mRNA encoding HPV16/18 antigens is taken up by host cells, translated into viral proteins, and presented on MHC I/II by dendritic and other antigen-presenting cells. This primes and expands HPV16/18-specific CD8+ cytotoxic and CD4+ helper T cells, promoting immune-mediated clearance of HPV-infected dysplastic cervical epithelial cells and lesion regression.
drug_name
RG002
nct_id_drug_ref
NCT06273553